OTU deubiquitinase with linear linkage specificity likeGenealiases: FAM105A · NET20
Q-omics provides the consensus-scored OTULINL profile across patient tissues and cancer cell-line models. OTULINL expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, OTULINL is differentially expressed in 12, with the highest sampling consensus in LUAD. Additionally, OTULINL protein abundance shows 21,152 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, LUAD, and LSCC as cancer lineages where OTULINL shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OTULINL — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OTULINL survival associations across molecular data types. OTULINL RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OTULINL RNA expression–survival associations across cancer types. High OTULINL expression shows unfavorable associations in UVM and STAD, but favorable associations in KIRC, SKCM, HNSC and PAAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for OTULINL RNA expression.
This table summarizes OTULINL tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 7. The strongest signals are observed in LUAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for OTULINL. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OTULINL shows lower tumor expression in LUAD, LUSC, KICH and KIRP and higher tumor expression in STAD and LIHC. The LUAD box plot shows higher OTULINL RNA expression in normal versus tumor tissue (log2 FC = −2.071, t-test p < 0.001).
This table shows molecular features associated with OTULINL in patient tissues and cancer cell lines. In patient samples, OTULINL shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, OTULINL RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in CNS and LUNG_SCLC.
